Progression‐free survival
lymphomas
LYMPHOMAS, DEL
The favor of upfront was demonstrated (Figure Progression‐free survival results. (A) PFS by treatment groups. (B) PFS by DEL. (C) PFS by lung involvement. (D) PFS by ICT.Patients with double‐expressor lymphomas (DEL) demonstrated (Figure Patients, treated by DA‐EPOCH‐R demonstrated (Figure Multivariate PFS analysis demonstrated the benefit in 3‐year PFS (Table Multivariate PFS analysis in all patients, There were too few relapses in the upfront group (Multivariate PFS analysis in the control group, 